Leading the elite Wall Street firm Cravath, he became a go-to adviser on mergers and acquisitions — “all the big deals that were going on in the ’80s and ’90s.” ...

Bristol Myers Squibb Co. closed 3.24% short of its 52-week high of $61.10, which the company reached on January 27th.

The company's blockbuster drug Keytruda contributed $29.48 billion in sales in 2024, but the first of its patent expirations begin in 2028.

As the major cost-cutting initiative at Bristol Myers Squibb rolls on, the company is launching another round of layoffs in ...

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical giant with a market capitalization of $120.8 billion, finds ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pfizer (PFE – Research Report) and Supernus ...

Cumberland Pharmaceuticals’ Duchenne muscular dystrophy (DMD) drug has improved the amount of blood pumped by the heart, ...

The results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...

Researchers have developed a computer model to help scientists identify tumor-fighting immune cells in patients with lung cancer treated with immune checkpoint inhibitors.

Since the first, seminal randomised controlled trial (RCT) in inflammatory bowel disease (IBD) in 1955,1 the central tenets ...

Bristol Myers Squibb Co. closed 1.88% below its 52-week high of $61.10, which the company reached on January 27th.

Bristol-Myers Squibb Co (BMY) stock saw a decline, ending the day at $58.95 which represents a decrease of $-0.19 or -0.32% from the prior close of $59.14. The stock opened at $59.18 and touched a low ...